BioHarvest Sciences Inc.

BioHarvest Sciences Inc.

NNASDAQ:BHST
1.38
USD
-0.12
(-8.31%)
BioHarvest Sciences Inc.
NASDAQ:BHST
(Nasdaq Stock Market)

Recent

price

1.38

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2019
2020
2021
2022
2023
2024
2025
TTM
USD
- -
- -
- -
- -
- -
- -
0.07
0.04
0.17
0.42
0.94
1.56
1.87
1.7
Revenue per Share
-1.24
-0.72
-0.33
-0.24
-0.28
-3.14
-1.8
-0.68
-0.79
-0.86
-0.93
-0.8
-0.6
-0.53
Basic EPS, GAAP
-1.28
-0.42
-0.42
-0.22
-0.27
-1.03
-0.82
-0.42
-0.68
-0.8
-0.74
-0.59
-0.52
-0.51
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.12
0.05
0.05
-0.2
0.46
1.35
-9.14
-0.2
0.22
-0.45
-1.09
0.08
1.12
0.87
Book Value per Share
0.12
0.05
0.05
-0.2
0.46
-0.38
-9.14
-0.2
0.22
-0.45
-1.09
0.08
1.12
0.87
Tangible Book Value per Share
- -
- -
- -
- -
1
2
3
10
12
13
14
16
18
21
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
2
5
13
25
35
35
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
-1,026.15
-1,557.07
-403.95
-193.02
-78.65
-27.75
-16.16
-17.99
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
2
2
Depreciation Expense
- -
- -
- -
- -
- -
-5
-5
-7
-10
-11
-13
-13
-11
-11
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
-2,435.78
-1,662.63
-467.51
-204.37
-99.15
-51.27
-32.27
-31.21
Profit Margin (%)
- -
- -
- -
- -
- -
1
-25
- -
3
-7
-17
-6
23
15
Working Capital
- -
- -
- -
- -
- -
- -
- -
2
2
2
1
9
13
11
LT Debt
- -
- -
- -
- -
- -
4
-27
-2
3
-6
-15
1
25
20
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-566.52
-630.03
- -
- -
-252.37
- -
- -
- -
- -
- -
- -
-83.17
-283.38
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2
3
4
LT Borrowings
2
1
- -
LT Finance Leases
10
10
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
118
98
65

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
31
28
26
Cash, Cash Equivalents & STI
23
20
16
Accounts Receivable, Net
2
2
3
Inventories
5
5
6
Total Current Liabilities
8
10
12
Payables & Accruals
4
6
6
ST Debt
2
3
4
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
32.45%
264.57%
1,813.38%
Free Cash Flow
122.62%
24.78%
0.65%
Net Income, GAAP
316.73%
12.89%
-13.77%
Sales/Revenue/Turnover
- -
171.72%
37%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5
6
7
7
25
2025
8
9
9
9
35
2026
9
9
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.48
-0.04
-0.16
- -
-0.8
2025
-0.13
-0.24
-0.14
- -
-0.6
2026
-0.12
-0.16
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company News

  • BioHarvest Sciences Inc. (BHST) Q3 2026 Earnings Call Transcript

  • BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Misses Revenue Estimates

  • BioHarvest Reports Third Quarter 2026 Financial Results and Provides Business Update

  • BioHarvest Sciences (NASDAQ:BHST) and Haleon (NYSE:HLN) Head to Head Contrast

  • Solesence (NASDAQ:SLSN) versus BioHarvest Sciences (NASDAQ:BHST) Financial Review

  • BioHarvest Sciences (NASDAQ:BHST) & Interparfums (NASDAQ:IPAR) Head to Head Analysis

  • BioHarvest Sciences to Report Third Quarter 2026 Financial Results on November 12, 2026

  • BioHarvest takes second plant-cell asset to commercial readiness

  • BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity

  • BioHarvest says its platform can produce target sweetener in Tate & Lyle program

  • Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme

  • BioHarvest Sciences launches buyback of up to 5% of shares

  • BioHarvest Sciences Announces Share Repurchase Program

  • BioHarvest Advances Botanical Synthesis Leadership as VINIA Daily Chews Unlock More Value from Its First Consumer Product

  • BioHarvest Sciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

  • Fiinu shares jump over 6% as Conister Bank platform enters production

  • BioHarvest Sciences plans Tel Aviv Stock Exchange dual listing

  • BioHarvest Sciences Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

  • BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript

  • BioHarvest Sciences Q2 Earnings Call Highlights